Tag: Valneva

Valneva's recently published 2025 annual results reveal a company at a strategic crossroads. While its core business demonstrates resilience, the ...

French vaccine specialist Valneva has unveiled its full-year 2025 results, presenting a nuanced financial picture that underscores a significant improvement ...

While Valneva prepares to release its full-year 2025 financial results this Tuesday, investor focus is firmly fixed elsewhere. The upcoming ...

The French vaccine developer Valneva has released preliminary figures for 2025 and issued initial guidance for the current fiscal year. ...

Investors in French vaccine developer Valneva are facing a period of intense uncertainty. The company's latest financial report presents a ...

A curious divergence is unfolding for Valneva's stock. While the biotech firm demonstrates significant operational improvements and dramatically curtails its ...

Despite recent market jitters affecting investor sentiment, the underlying financial performance of French vaccine specialist Valneva tells a different story. ...

The French vaccine developer Valneva has staged an impressive financial recovery, transforming a €69.3 million loss into a substantial €24.7 ...

The biotechnology sector is renowned for its volatility, but the upcoming financial report from Valneva could unsettle even the most ...

The fate of Valneva, along with millions in investor capital, hinges on critical developments unfolding in the coming weeks. Behind ...